Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | XBP1 | P17861 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.38 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.38 |
| ▸ | GGT1 | P19440 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10087856 | 0.85 | ALDH1A1 (0.40) | ELANEKDM4EHSD17B10CYP1A2CYP2C9 | |
| SCHEMBL3016523 | 0.83 | SMN1; SMN2 (0.39) | KDM4ECYP1A2CYP2C9LMNAHPGD | |
| SCHEMBL1282947 | 0.81 | HSD17B10 (0.50) | ELANEKDM4EHSD17B10CYP1A2CYP2C9 | |
| SCHEMBL7275094 | 0.81 | REN (0.42) | MAPTNPSR1ALDH1A1TDP1KMT2A | |
| SCHEMBL1300248 | 0.81 | CYP3A4 (0.45) | CYP1A2CYP2C9LMNAMAPTALDH1A1 | |
| SCHEMBL6723581 | 0.81 | ELANE (0.44) | ELANEKDM4EHSD17B10CYP1A2CYP2C9 | |
| SCHEMBL4731573 | 0.80 | HSD17B10 (0.63) | ELANEKDM4EHSD17B10CYP1A2CYP2C9 | |
| SCHEMBL2854249 | 0.80 | KMT2A (0.50) | ELANEKDM4EHSD17B10CYP1A2CYP2C9 | |
| SCHEMBL19625924 | 0.80 | KDM4E (0.62) | KDM4EHSD17B10CYP1A2CYP2C9LMNA | |
| SCHEMBL9850317 | 0.80 | KDM4E (0.62) | KDM4EHSD17B10CYP1A2CYP2C9LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853204-B2 | Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the RSV fusion protein | ARROW THERAPEUTICS LIMITED (GB) | 2014-10-07 | — | — | US | disclosed |
| EP-2707363-A1 | A PROCESS FOR THE PREPARATION OF BENZYL [(3AS,4R,6S,6AR)-6-HYDROXY-2,2- DIMETHYLTETRAHYDRO-3AH-CYCLOPENTA[D][1,3]DIOXOL]-4-YL]CARBAMATE AND INTERMEDIATES IN THE PROCESS | AstraZeneca AB (SE) | 2014-03-19 | — | — | EP | disclosed |
| WO-2012158099-A1 | A PROCESS FOR THE PREPARATION OF BENZYL [(3AS,4R,6S,6AR)-6-HYDROXY-2,2- DIMETHYLTETRAHYDRO-3AH-CYCLOPENTA[D][1,3]DIOXOL]-4-YL]CARBAMATE AND INTERMEDIATES IN THE PROCESS | ASTRAZENECA AB (SE) | 2012-11-22 | — | — | WO | disclosed |
| US-8119630-B2 | Benzodiazepine derivatives and pharmaceutical compositions containing them | ARROW THERAPEUTICS LIMITED (GB) | 2012-02-21 | — | — | US | disclosed |
| US-8039616-B2 | Benzodiazepine derivatives for treating hepatitis C infection | ASTRAZENECA AB (SE) | 2011-10-18 | — | — | US | disclosed |
| US-20100015063-A1 | Benzodiazepine Derivatives and Pharmaceutical Compositions Containing Them | ARROW THERAPEUTICS LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
| US-20090318427-A1 | BENZODIAZEPINE DERIVATIVES FOR TREATING HEPATITIS C INFECTION | ARROW THERAPEUTICS LIMITED (GB) | 2009-12-24 | — | — | US | disclosed |
| EP-1727551-B1 | PHARMACEUTICAL COMPOSITION COMPRISING A BENZODIAZEPINE DERIVATIVE AND A INHIBITOR OF THE RSV FUSION PROTEIN | ARROW THERAPEUTICS LTD (GB) | 2009-09-09 | — | — | EP | disclosed |
| US-7582624-B2 | Benzodiazepine derivatives and pharmaceutical compositions containing them | ARROW THERAPEUTICS LIMITED (GB) | 2009-09-01 | — | — | US | disclosed |
| EP-1727550-B1 | PHARMACEUTICAL COMPOSITION COMPRISING A BENZODIAZEPINE DERIVATIVE AND AN INHIBITOR OF THE RSV FUSION PROTEIN | ARROW THERAPEUTICS LTD (GB) | 2009-07-29 | — | — | EP | disclosed |
| US-20070185096-A1 | Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the rsv fusion protein | NOVARTIS PHARMACEUTICALS CORPORATION (US) | 2007-08-09 | — | — | US | disclosed |
| US-20070142403-A1 | Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the rsv fusion protein | NOVARTIS PHARMACEUTICALA CORPORATION (US) | 2007-06-21 | — | — | US | disclosed |
| WO-2007034127-A1 | BENZODIAZEPINE DERIVATIVES FOR TREATING HEPATITIS C INFECTION | ARROW THERAPEUTICS LIMITED (GB) | 2007-03-29 | — | — | WO | disclosed |
| EP-1727550-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A BENZODIAZEPINE DERIVATIVE AND AN INHIBITOR OF THE RSV FUSION PROTEIN | Arrow Therapeutics Limited (GB) | 2006-12-06 | — | — | EP | disclosed |
| EP-1727551-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A BENZODIAZEPINE DERIVATIVE AND A INHIBITOR OF THE RSV FUSION PROTEIN | Arrow Therapeutics Limited (GB) | 2006-12-06 | — | — | EP | disclosed |
| US-20060040923-A1 | Benzodiazepine derivatives and pharmaceutical compositions containing them | ARROW THERAPEUTICS LIMITED (GB) | 2006-02-23 | — | — | US | disclosed |
| WO-2005089771-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A BENZODIAZEPINE DERIVATIVE AND A INHIBITOR OF THE RSV FUSION PROTEIN | ARROW THERAPEUTICS LIMITED (GB) | 2005-09-29 | — | — | WO | disclosed |
| WO-2005089769-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A BENZODIAZEPINE DERIVATIVE AND AN INHIBIT OR OF THE RSV FUSION PROTEIN | ARROW THERAPEUTICS LIMITED (GB) | 2005-09-29 | — | — | WO | disclosed |
| EP-0331105-A2 | 1,2-Hydroxy phosphonates and derivatives thereof | E.R. Squibb & Sons, Inc. (US) | 1989-09-06 | — | — | EP | disclosed |
| EP-0274999-A2 | Resin support for solid phase peptide synthesis | MONSANTO COMPANY (US) | 1988-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185096-A1 | Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the rsv fusion protein | GABRP, TSPO, GABRA1 | ELANE 4428/4885KDM4E 4254/4885HSD17B10 3109/4885 |
| US-20060040923-A1 | Benzodiazepine derivatives and pharmaceutical compositions containing them | GABRA6, CNR1, SIGMAR1 | ELANE 3318/4885KDM4E 3634/4885HSD17B10 1433/4885 |
| US-20090318427-A1 | BENZODIAZEPINE DERIVATIVES FOR TREATING HEPATITIS C INFECTION | CNR1, GABRA6, SIGMAR1 | ELANE 3045/4885KDM4E 3957/4885HSD17B10 997/4885 |
| US-20100015063-A1 | Benzodiazepine Derivatives and Pharmaceutical Compositions Containing Them | GABRA6, CNR1, SIGMAR1 | ELANE 3297/4885KDM4E 3550/4885HSD17B10 1438/4885 |
| US-20070142403-A1 | Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the rsv fusion protein | GABRP, TSPO, GABRA1 | ELANE 4428/4885KDM4E 4254/4885HSD17B10 3109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.